Related Experiment Video
Updated: Aug 3, 2025
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Interpreting the Therapeutic Efficiency of Multifunctional Hybrid Nanostructure against Glioblastoma
Zemin Ou1, Xinjian Li1, Yun You1
1Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 10700, China.
Abstract:
Glioblastoma is considered the most fatal malignant brain tumor that starts from the central nervous system (CNS), where the blood-brain barrier (BBB) remains the biggest challenge for active targeting of drugs in malignant brain tumor. Thereby, we have designed a paclitaxel PTX@ANG/FA-NPs hybrid novel nanodrug delivery system that can overcome the clinical BBB. The structural and morphological characterization of PTX@ANG/FA-NPs confirmed successful synthesis of nanomicelles with the size range of about 160 to 170 nm. The overall repressive effect of PTX@ANG/FA-NPs on human glioblastoma U251 cells was 1.2-times that of PTX alone. In vitro cellular uptake assay also demonstrated that the dual-targeted nanoparticles (NPs) were more easily taken up by glioblastoma U251 cells. Although the antiglioblastoma activity was confirmed by cell migration assay, apoptosis assay, and cellular uptake assay, the absorption was studied by in vivo fluorescence imaging and brain distribution. The synthesized PTX@ANG/FA-NPs probe significantly inhibited the migration of U251 within the cells and promoted the apoptosis process. Moreover, the RhB@ANG/FA-NPs and PTX@ANG/FA-NPs showed higher accumulating potential at sites of tumor BBB disruption. The novel nanodrug delivery system mediated enhanced distribution of drugs at the targeted site for therapeutics efficacies against glioblastomas across the BBB.
Insights
A novel paclitaxel-loaded nanodrug delivery system (PTX@ANG/FA-NPs) effectively targets glioblastoma cells and crosses the blood-brain barrier (BBB). This system enhances drug distribution and therapeutic efficacy against brain tumors.
Area of Science:
- Nanotechnology
- Neuro-oncology
- Drug Delivery Systems
Background:
- Glioblastoma is a highly fatal brain tumor with limited treatment options due to the blood-brain barrier (BBB).
- The BBB poses a significant challenge for delivering therapeutic agents to malignant brain tumors.
- Effective drug delivery systems are crucial for improving glioblastoma treatment outcomes.
Purpose of the Study:
- To design and characterize a novel hybrid nanodrug delivery system (PTX@ANG/FA-NPs) capable of overcoming the BBB.
- To evaluate the efficacy of PTX@ANG/FA-NPs against human glioblastoma U251 cells.
- To investigate the in vivo distribution and therapeutic potential of the nanodrug delivery system.
Main Methods:
- Synthesis and characterization of paclitaxel-loaded nanoparticles (PTX@ANG/FA-NPs).
- In vitro studies including cellular uptake, cell migration, and apoptosis assays on glioblastoma U251 cells.
- In vivo fluorescence imaging and brain distribution studies to assess nanoparticle accumulation.
Main Results:
- Successful synthesis of PTX@ANG/FA-NPs with a size range of 160-170 nm.
- PTX@ANG/FA-NPs exhibited 1.2-times higher repressive effect on glioblastoma cells compared to paclitaxel alone.
- Enhanced cellular uptake and significant inhibition of cell migration, along with promotion of apoptosis.
- Higher accumulation of nanoparticles at tumor sites with BBB disruption, indicating successful BBB crossing.
Conclusions:
- The PTX@ANG/FA-NPs system effectively overcomes the BBB for glioblastoma treatment.
- This novel nanodrug delivery system demonstrates enhanced therapeutic efficacy by improving drug distribution to the tumor site.
- The findings suggest a promising strategy for improving glioblastoma therapy through targeted nanomedicine.
